top of page

A major step towards individualized cancer therapy

  • Jun 13, 2018
  • 2 min read


The team opened a small window in eggshells and implanted ovarian tumour cells on top of the vascular membrane surrounding 10-day-old chicken embryos. @ Izumi Mindy Takamiya

Fuyuhiko Tamanoi of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and colleagues in the US succeeded in establishing a versatile, powerful and convenient model to analyse human cancer.

They developed a 'chicken egg tumour model' in which cultured ovarian cancer cells are transplanted on top of the membrane that surrounds a 10-day-old chicken embryo. An ovarian tumour forms on top of the membrane within three days of transplantation.

The team had similar results when they used ovarian tumour samples taken directly from patients, showing that their chicken egg model provides a convenient system for replicating human cancer. This conclusion is supported by their detailed characterization of the tumour, demonstrating that it possesses all major cancer features. "We were surprised when the tumour was formed in three days," says Tamanoi. " This is very rapid considering that it takes weeks to do the same with mice. We can start using this model to test for anti-cancer drugs tailored to each cancer patient's needs. The process can be completed within one week," he says. This is a major step toward individualized medicine for cancer patients.

Tamanoi's team, in collaboration with colleagues in France and Saudi Arabia, also developed a new type of biodegradable silica nanoparticle called 'biodegradable PMO', which is only 200 nanometres in size. The nanoparticles were loaded with the anti-cancer drug doxorubicin and were tested on human ovarian tumour established in the chicken egg.

The biodegradable PMO carrying doxorubicin quickly eliminated the human ovarian tumours without affecting other organs in the chicken embryo. When a smaller amount of the drug, not enveloped in the nanoparticles, was injected in the egg, severe organ damage ensued. This indicates that the team's nanoparticles prevent anti-cancer drug side effects due to their ability to directly target the tumour.

The chicken egg model has several advantages over existing models, such as mouse models, for testing anti-cancer therapies. The tumours form much more rapidly on the chicken embryonic membranes than in mice due to the rich nutrient environment and the incomplete immune system at this stage of embryonic development. Fertilized chicken eggs are also less expensive to use than immune-compromised mice making the model suitable for high throughput experiments.

Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer Binh Thanh Vu, Sophia Allaf Shahin, Jonas Croissant, Yevhen Fatieiev, Kotaro Matsumoto, Tan Le-Hoang Doan, Tammy Yik, Shirleen Simargi, Altagracia Conteras, Laura Ratliff, Chiara Mauriello Jimenez, Laurence Raehm, Niveen Khashab, Jean-Olivier Durand, Carlotta Glackin & Fuyuhiko Tamanoi Scientific Reports Volume 8, Article number: 8524 (2018)

Contact information:

Fuyuhiko Tamanoi

Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) fuyut@microbio.ucla.edu

Kyoto University

 
 
 

Comments


FREE LISTING

Get Found by Gobal Nanotech Buyer

Join 2,000+ companies in our directory. Claim your profile in 2 minutes.

Reach 220k+ professionals

Instant credibility boost

Start free, upgrade anytime

List your Nanotech Products

Showcase your innovations to our 220k+ network of industry professionals and 14k newsletter subscribers

Stay Ahead in Nanotech

Monthly insights, breakthroughs, and opportunities delivered to 14,000+ industry professionals.

Thank you registering!

More News

Join the Global Nanotechnology Network

Connect with 220k+ nanotech professionals across our network and grow your business visibility

FOR COMPANIES

  • Free basic profile

  • Showcase your products

  • Connect with global buyers

  • Premium options available

STAY INFORMED

  • Monthly industry insights

  • Latest breakthroughs & trends

  • New products & innovations

  • Exclusive opportunities

bottom of page